A Omni, the only digital platform for prescription plans that operates in any pharmacy in Brazil, welcomes the investment fund Norte Ventures and announces its third round in less than two years of operation in the healthcare market. The investor joins to contribute to the strategy for future capital rounds, with a large know-how in this segment.
The startup does not disclose its market value, but confirms that it was a valuation the same as that practiced at the time of Greenrock's entry, which contributed 10 million reais, in May of this year.
Omni Saúde was founded in May 2023 by healthcare entrepreneur Fernando Domingues, co-founder of Conexa Saúde, the largest independent Telemedicine platform and Digital Health Ecosystem in Latin America, and Cannect Life, a medicinal cannabis marketplace that has already raised over R$30 million, and by Leopoldo Veras, a professional with over 25 years of experience in healthcare management and experience working for health plan providers, healthtechs, benefits administrators, and pharmaceutical plan providers.
Considered the first company to offer a medication plan that operates in any pharmacy in Brazil, with an average cost of R$1,000,000 per employee, Omni aims to make this benefit indispensable for the HR department of companies across various sectors, playing a key role in democratizing access to medication. With a focus on user experience, the company already has over 15,000 medication plans sold, representing a threefold increase in the first quarter of 2024 alone, compared to last year. Omni aims to double the number of patients served in the second half of the year, reaching 50,000, which would result in annual revenue of nearly R$1,000,000,000. Designed to serve employees of medium- and large-sized companies, healthtech already has several renowned clients such as Dasa, Spoleto, Alper Seguros, Qualicorp, Riachuelo, Vitta/Stone, among others.
"This investment will allow us to strengthen our internal operations, optimize processes, and invest even more in the health of our clients' employees. The ability to expand our team and implement advanced technologies is essential to maintain our leadership position and meet growing market demands," comments Fernando Domingues, co-founder and CEO of Omni. "Knowing Norte Ventures' interest in co-investing in companies with high growth potential, this funding reinforces our commitment to delivering significant advances to address the challenges of the pharmaceutical industry and revolutionize pharmaceutical care. The partnership with Norte is a testament to the confidence in our vision and the transformative impact our technologies can have on people's health and well-being," he adds.
"We've known Fernando since Cannect and Conexa, and he's assembled a very impressive team at Omni. The company addresses a significant pain point, considering the high number of chronic patients in Brazil and the lack of health insurance coverage for this type of expense. With a superior value proposition, product, and significant traction, the decision to invest was relatively easy. Finally, we're delighted to co-invest again with Greenrock, which brings very strong validation in the healthcare sector," says Pedro Teo, partner at Norte Ventures.
To fill this gap in pharmaceutical assistance in the Brazilian supplementary health system, healthtech It also works by promoting information and raising awareness among patients and the entire ecosystem about the rational and safe consumption of medicines, as well as reinforcing the importance of adherence to treatment, especially in cases of chronic diseases, in addition to the dangers of self-medication.
The company also has angel investors such as Jaime de Paula, founder of Neoway, Massanori Shibata Jr, CEO of Dr. Consulta, co-founder and controller of the Spoleto brands, Paulo Yoo, director of ecosystem and innovation at Dr. Consulta, and Jorge Oliveira, executive director of Unimed Nacional.
In June 2023, Omni received investment seed of R$5 million, led by VEC Investments.
